ClinicalTrials.gg
Not yet recruitingNCT07713771mirtapatchUpdated Aug 10, 2026

Effectiveness of Mitragynine Topical Patch for Pain Reduction in Myofascial Pain Syndrome

A Phase 3 interventional study of mitragynine topical patch from kratom and Placebo in Topical Analgesia and Myofascial Pain Syndrome - Neck, sponsored by Prince of Songkla University. Not yet recruiting at 1 site in Thailand. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Prince of Songkla University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Myofascial Pain Syndrome (MPS) is one of the leading causes of both acute and chronic musculoskeletal pain encountered in clinical practice.¹ The most common presentation is low back pain, followed by pain in the neck and scapular regions.² These symptoms significantly affect quality of life and work performance. A common site involved in neck pain syndrome is the trapezius muscle, which may cause pain in the shoulder, neck, and occipital region. In some patients, neurological symptoms such as goosebumps or dizziness may also occur.³ Pain can occur in individuals of all age groups and may be either acute or chronic. It can arise from injuries or various diseases. Pain may result from different pathologies, including nociceptive pain, neuropathic pain, or a combination of both. Current medical treatment guidelines include both conventional medications and herbal extract-based therapies. In the 2022 National List of Essential Herbal Medicines of Thailand, several herbal formulations are indicated for pain relief. Oral preparations include Khasai Sen, Thorani Sandhakhat, and Ya Phasom Thao Wan Priang, while topical preparations include chili-based formulations, plai preparations, and plai oil. These remedies are indicated for the relief of body aches and muscle pain.⁶ Kratom, or *Mitragyna speciosa* (Korth.) Havil., is a plant belonging to the Rubiaceae family. In southern Thailand, it is commonly known as "Thom." Kratom leaves contain a variety of chemical constituents, including alkaloids, flavonoids, triterpenes, and phenolic compounds. Among these, indole alkaloids represent the major group. The principal active compound is mitragynine, which accounts for approximately two-thirds of the total alkaloid content, or about 66% by weight.⁷ Pharmacologically, orally administered mitragynine affects both the autonomic and central nervous systems. It possesses analgesic properties through binding to opioid receptors. Additionally, it reduces pain signal transmission to the brain via the noradrenergic and serotonergic systems.⁸ The mitragynine pain-relief patch used in this study is a product containing kratom extract formulated to deliver 10 milligrams of mitragynine per patch. It is designed as a topical patch, allowing the active ingredient to be absorbed into the outer layers of the skin without entering the bloodstream.¹¹ The patch consists of sodium alginate, pectin, and agar, which are naturally derived polymers commonly used as pharmaceutical excipients. The hypothesis of this study is that this locally acting "mitragynine pain-relief patch" can reduce pain and inflammation through the TRPV1 receptor mechanism described above.

Neck, shoulder, and upper back pain are among the most common reasons patients attend general practice, orthopedic, and rehabilitation clinics. Patients with chronic myofascial pain syndrome (defined as pain persisting for more than three months) may be treated using various approaches depending on symptom severity, accessibility of services, and individual suitability. These approaches include oral medications, topical agents, local injections, acupuncture, physical therapy, and muscle stretching exercises.

Many patients may have contraindications to oral medications, acupuncture, or regular attendance at physical therapy sessions, which can negatively affect their overall quality of life. Currently, topical medications are commonly prescribed for these patients at Hospital; however, treatment outcomes are often suboptimal. Moreover, most topical preparations produce a warming effect and may easily cause skin irritation, particularly in elderly patients with fragile skin. If the mitragynine pain-relief patch demonstrates effective pain reduction, it may be further developed as an alternative treatment option for these patients.

The objective of this study is to evaluate the efficacy of a mitragynine-containing kratom pain-relief patch in patients with myofascial pain syndrome, compared with a placebo patch (a patch containing only the base formulation without kratom extract), and to determine whether there is a difference in pain-relief response between the two groups and, if so, how that difference manifests.

Read the detailed description
  1. Study Design Double-blinded, placebo-controlled randomized controlled trial
  2. Study Setting Rehabilitation Clinic, hospital
  3. Target Population Individuals with pain in the shoulder and neck region.
  4. Study Population Patients with subacute myofascial pain syndrome involving the upper trapezius muscle.
  5. Inclusion Criteria - Patients aged 18-50 years.

    • Experiencing neck or shoulder pain for more than 3 months.
    • Diagnosed with myofascial pain syndrome, with the most tender trigger point located in the upper trapezius muscle and a pain score between 30-60 mm measured using the Visual Analogue Scale (VAS).
  6. Exclusion Criteria - History of other neck-related conditions (e.g., whiplash injury, cervical radiculopathy, fibromyalgia syndrome, cervical spine surgery and/or fracture).

    - History of systemic diseases (e.g., rheumatism, multiple sclerosis, cervical myelopathy), hepatitis, liver failure, or kidney disease (serum creatinine > 2.0 mg/dL).

    - Symptoms or conditions contraindicating the use of patches, such as wounds or infections at the painful site.

    - History of allergy to paracetamol or kratom.

    • History of allergy to adhesive patches/plasters.
    • Pregnant or breastfeeding women.
    • Receipt of treatment with analgesics other than paracetamol, physical therapy, dry needling/acupuncture, massage, or topical medications within the previous week.
    • Individuals who are unable to read or write.
  7. Participant Withdrawal Criteria - Participants experiencing severe allergic reactions (e.g., anaphylaxis, severe rash, or intolerable itching).

    • Receipt of treatments other than paracetamol or any interventions outside those specified in the study during the follow-up period.
    • Participants who wish to withdraw from the study.
  8. Study Termination Criteria The study will be terminated if participants experience significant adverse events, including severe allergic reactions (anaphylaxis) or systemic side effects such as nausea and vomiting, in at least 7 participants, representing 10% of the sample size.
  9. Sample Size 1. Irritation testing group: 10 healthy volunteers aged 18-50 years. 2. Efficacy testing group: 64 participants, calculated using the following formula: Sample size calculation for a randomized controlled trial with a continuous outcome μ_trt = mean VAS change in the treatment group μ_con = mean VAS change in the control group σ_trt = SD in the treatment group σ_con = SD in the control group λ = 1; α = 0.05; β = 0.2 The calculation was based on the study by Hsieh (2009) on the use of a diclofenac patch for reducing pain in the upper trapezius muscle.

Estimated values:

μ_trt = 2.57; μ_con = 3.92 σ_trt = 1.75; σ_con = 1.80 n_trt = 28; n_con = 28

Assuming a 10% dropout rate:

28 / 0.9 ≈ 32 participants per group Therefore, the total sample size ≈ 64 participants. 10 Variables and Operational Definitions Independent Variable

- Pain intensity: Used to indicate the level of pain on a scale ranging from 0-100 mm.

Dependent Variable

- Satisfaction score: Measured using a 5-point Likert scale with five levels of rating.

Confounding Variables

  • Paracetamol consumption: Date and number of tablets taken will be recorded.
  • Neck muscle stretching exercises: Date and frequency of stretching exercises will be recorded.
02

Conditions studied

  • Topical Analgesia
  • Myofascial Pain Syndrome - Neck

Keywords

  • mirtagynine
  • kratom patch
  • topical patch
  • pain reduction
03

In context

Myofascial Pain Syndromes

340 studies on the registry are indexed under Myofascial Pain Syndromes; 67 are open to participants now.

This study's planned enrollment of 64 is above the median of 51 across 308 interventional studies indexed under Myofascial Pain Syndromes.

Browse Myofascial Pain Syndromes studies →

Lead sponsor

Prince of Songkla University is the lead sponsor of 116 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Patients aged 18-50 years.
  • Experiencing neck or shoulder pain for more than 3 months.
  • Diagnosed with myofascial pain syndrome, with the most tender trigger point located in the upper trapezius muscle and a pain score between 30-60 mm measured using the Visual Analogue Scale (VAS).

Exclusion criteria

Exclusion Criteria:

  • - History of other neck-related conditions (e.g., whiplash injury, cervical radiculopathy, fibromyalgia syndrome, cervical spine surgery and/or fracture).
  • History of systemic diseases (e.g., rheumatism, multiple sclerosis, cervical myelopathy), hepatitis, liver failure, or kidney disease (serum creatinine > 2.0 mg/dL).
  • Symptoms or conditions contraindicating the use of patches, such as wounds or infections at the painful site.
  • History of allergy to paracetamol or kratom.
  • History of allergy to adhesive patches/plasters.
  • Pregnant or breastfeeding women.
  • Receipt of treatment with analgesics other than paracetamol, physical therapy, dry needling/acupuncture, massage, or topical medications within the previous week.
  • Individuals who are unable to read or write.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    treatment group

    topical patch contains of mirtagynine 10 mg

    Drug: mitragynine topical patch from kratom

  • Placebo comparator
    control group

    topical patch similar to treatment group except mirtagynine extract

    Drug: Placebo

Interventions

  • Drugmitragynine topical patch from kratom

    mirtagynine topical patch contains of 10 mg

  • DrugPlacebo

    topical patch similar to active patch but no mirtagynine

06

What researchers measure

Primary outcomes

  1. pain score

    * Pain intensity: Used to indicate the level of pain on a scale ranging from 0-100 mm. * compared mean VAS score between group

    Time frame: 3 days after used

Secondary outcomes

  1. satisfaction score

    Satisfaction score: Measured using a 5-point Likert scale with five levels of rating.

    Time frame: 3 days after used

07

Study locations

1 site
08

References and documents

Publications

  • Kruegel AC, Gassaway MM, Kapoor A, Varadi A, Majumdar S, Filizola M, Javitch JA, Sames D. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. J Am Chem Soc. 2016 Jun 1;138(21):6754-64. doi: 10.1021/jacs.6b00360. Epub 2016 May 18. PubMed 27192616 ↗
  • Goodwin B, Mitchell J, Major E, Podwojniak A, Brancaccio H, Rusinak K, King M, Tahir H. The efficacy of topical 8% capsaicin patches for the treatment of postsurgical neuropathic pain: a systematic review. Pain Manag. 2024 Oct-Nov;14(10-11):591-598. doi: 10.1080/17581869.2024.2433931. Epub 2024 Nov 26. PubMed 39589498 ↗
  • Hsieh LF, Hong CZ, Chern SH, Chen CC. Efficacy and side effects of diclofenac patch in treatment of patients with myofascial pain syndrome of the upper trapezius. J Pain Symptom Manage. 2010 Jan;39(1):116-25. doi: 10.1016/j.jpainsymman.2009.05.016. Epub 2009 Oct 12. PubMed 19822404 ↗
  • Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull (Tokyo). 2004 Aug;52(8):916-28. doi: 10.1248/cpb.52.916. PubMed 15304982 ↗
  • Cerezo-Tellez E, Torres-Lacomba M, Mayoral-Del Moral O, Sanchez-Sanchez B, Dommerholt J, Gutierrez-Ortega C. Prevalence of Myofascial Pain Syndrome in Chronic Non-Specific Neck Pain: A Population-Based Cross-Sectional Descriptive Study. Pain Med. 2016 Dec;17(12):2369-2377. doi: 10.1093/pm/pnw114. Epub 2016 Jun 20. PubMed 28025371 ↗
  • Borg-Stein J, Simons DG. Focused review: myofascial pain. Arch Phys Med Rehabil. 2002 Mar;83(3 Suppl 1):S40-7, S48-9. doi: 10.1053/apmr.2002.32155. PubMed 11973695 ↗

Individual participant data

Plan to share: No — This study is an intellectual property of out team. We have plan to develop product in the future.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 20, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
Oct 31, 2029
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07713771
Responsible party
SUTTIPONG TIPCHATYOTIN (assistant professor, Prince of Songkla University) — Principal investigator
First posted
Jul 20, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 31, 2028 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Aug 10, 2026

Study contacts

suttipong tipchatyotin, m.d.
Contact
tsuttipo@medicine.psu.ac.th
+66848559898
sumairao toateng, B.Sc.
Contact
sumairao.t@psu.ac.th
+6674451601
suttipong tipchatyotin, m.d.
principal investigator · Prince of Songkla University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion